Kisqali increases overall survival in advanced breast cancer patients by 12 months
Kisqali plus letrozole achieved a median overall survival (OS) of…
Kisqali plus letrozole achieved a median overall survival (OS) of over five years (63.9 months), with OS benefit increasing over time, according to newly published data.